Atopic dermatitis (AD) is the most common inflammatory skin
disease, with a large and currently unmet need for effective therapeutics. AD
and psoriasis, another common skin disease, are recognized as polar
inflammatory skin diseases. Psoriasis is emerging as an IL-23/TH17-skewed
disease, whereas AD is considered to be TH2-centered. These
distinctions are relevant to emerging therapies for each. To date, the
characterization of AD in different patient populations has made the assumption
that disease mechanisms are similar across them. Noda et al present evidence
that this is not so (J Allergy Clin Immunol 2015; 136: 1254-1264).
The prevalence of AD among adults in Asia is 7% to 10%,
which is considerably higher than in other populations. In addition, prominent
TH17 activation has been observed in blood and acute AD lesions of
Asian AD patients. The high prevalence and increased IL-17+ T-cell
expansion suggest that an Asian AD phenotype may have different immune and
barrier characteristics than the European American (EA) one. The authors have
thus directly compared AD in European American (EA) and Asian (Japanese and
Korean) populations. Their report classifies an Asian AD phenotype that is
mixed between the EA AD and psoriasis phenotypes, with features atypical to AD
such as parakeratosis and a unique cytokine profile with co-activation of the TH2
and TH17 axes. Even in the presence of increased IgE levels, Asian
AD shows significantly higher induction of TH17 and TH22-related
cytokines. Interestingly, psoriasis has a very low prevalence in Asian
populations.
Further studies are needed to clarify the extent to which
these differences are genetic, environmental, and/or microbiome related; for
example, a similar study of Asian AD patients and Asian American AD patients.
Additionally, FLG mutation status was unknown for all of the patients the
current study includes. Regardless, the differences in the phenotype of Asian
AD presented here call for similar description of other racial groups, and they
provide a rationale for testing of IL-17/IL-23-targeted therapeutic strategies
that have been successfully used in the treatment of psoriasis, in addition to
those that are TH2-specific.
شركة تنظيف ستائر بمكة
ReplyDeleteشركة جلي بلاط بمكة
شركة مكافحة حشرات بالدمام
شركة كشف تسربات بالدمام
شركة عزل اسطح بالدمام
شركة تسليك مجاري بالدمام